Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| ACADAcadia Pharmaceuticals Inc | $10.4M | 7.6% | +233.3% |
| XERSXeris Biopharma Holdings Inc | $9.7M | 7.2% | +20.0% |
| BMRNBiomarin Pharmaceutical Inc | $8.2M | 6.0% | +75.0% |
| PRAXPraxis Precision Medicines I | $7.5M | 5.5% | |
| RAREUltragenyx Pharmaceutical In | $6.8M | 5.0% | +17.6% |
| AGIOAgios Pharmaceuticals Inc | $6.1M | 4.5% | New |
| INSMInsmed Inc | $5.5M | 4.0% | New |
| Crinetics Pharmaceuticals InCUSIP 22663K107 | $5.4M | 3.9% | New |
| ZNTLZentalis Pharmaceuticals Inc | $5.0M | 3.7% | −16.7% |
| PCVXVaxcyte Inc | $4.8M | 3.5% | +42.9% |
| ANNXAnnexon Inc | $4.7M | 3.4% | +370.6% |
| TVTXTravere Therapeutics Inc | $4.7M | 3.4% | −25.9% |
| TNXPTonix Pharmaceuticals Hldg C | $4.3M | 3.2% | New |
| BBIOBridgebio Pharma Inc | $4.3M | 3.1% | New |
| AXSMAxsome Therapeutics Inc. | $4.0M | 2.9% | −60.0% |
| CTNMContineum Therapeutics Inc | $3.4M | 2.5% | +44.4% |
| LXRXLexicon Pharmaceuticals Inc | $3.1M | 2.2% | +40.9% |
| KURAKura Oncology Inc | $3.0M | 2.2% | New |
| DBVTDbv Technologies S A | $3.0M | 2.2% | +80.0% |
| GMABGenmab A/s | $2.8M | 2.1% | +25.0% |
| CYTKCytokinetics Inc | $2.8M | 2.1% | New |
| MLYSMineralys Therapeutics Inc | $2.8M | 2.0% | +25.0% |
| SLNSilence Therapeutics PLC | $2.4M | 1.8% | −60.6% |
| NUVBNuvation Bio Inc | $2.1M | 1.5% | New |
| Wave Life Sciences LtdCUSIP Y95308105 | $1.9M | 1.4% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ZNTLZentalis Pharmaceuticals Inc | December 31, 2025 | +259.3% | $5.0M |
| LXRXLexicon Pharmaceuticals Inc | December 31, 2025 | +108.7% | $3.1M |
| TVTXTravere Therapeutics Inc | March 31, 2026 | +91.2% | $4.7M |
| SLNSilence Therapeutics PLC | December 31, 2025 | +80.6% | $2.4M |
| RAREUltragenyx Pharmaceutical In | December 31, 2025 | +45.2% | $6.8M |
| AXSMAxsome Therapeutics Inc. | March 31, 2026 | +44.8% | $4.0M |
| ORICOric Pharmaceuticals Inc | December 31, 2025 | +32.4% | $1.3M |
| PCVXVaxcyte Inc | December 31, 2025 | +26.0% | $4.8M |
| CTNMContineum Therapeutics Inc | March 31, 2026 | +25.5% | $3.4M |
| BEAMBeam Therapeutics Inc | December 31, 2025 | +23.8% | $1.4M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $5.6M
- Amicus TherapeuticCUSIP 03152W109 was $5.3M
- VSTMVerastem Inc was $4.3M
- ARWRArrowhead Pharmaceuticals In was $3.5M
- MLTXMoonlake Immunotherapeutics was $3.2M
- ARDXArdelyx Inc was $2.7M
- Catalyst Pharmaceuticals IncCUSIP 14888U101 was $2.0M
- LGNDLigand Pharmaceuticals Inc was $1.6M
- EWTXEdgewise Therapeutics Inc was $1.5M
- IDYAIdeaya Biosciences Inc was $820K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +19.9% | +14.8% |
| March 31, 2026 | +1.9% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Ishara Investments LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2111609&type=13F-HR&dateb=&owner=include&count=40CIK 2111609
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2111609/000211160926000004/Filed August 14, 2026 · accession 0002111609-26-000004